Antibody Discovery Platform
•70 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (70)
%
| Company | Market Cap | Price |
|---|---|---|
|
Antibody Discovery Platform reflects a dedicated platform for antibody discovery and development.
|
$120.19B |
$98.46
|
|
Antibody Discovery Platform reflects VelocImmune-based antibody discovery and related platform capabilities.
|
$60.96B |
$564.63
-0.82%
|
|
Antibody Discovery Platform tag reflecting ARGx's Immunology Innovation Platform and pipeline-in-a-product strategy.
|
$47.65B |
$796.92
-0.76%
|
|
Antibody Discovery Platform reflects Takeda's antibody discovery capabilities used in developing biologics.
|
$43.58B |
$27.33
-2.62%
|
|
BNT327 and related antibody programs imply the use of an antibody discovery platform.
|
$24.47B |
$102.06
-2.54%
|
|
Genmab maintains an Antibody Discovery Platform encompassing its bispecific and related antibody technologies.
|
$21.05B |
$31.81
-0.28%
|
|
Antibody Discovery Platform tag is applicable due to Genmab’s proprietary antibody platforms (DuoBody, HexaBody) that enable development of bispecifics and ADCs.
|
$19.49B |
$315.00
|
|
Roivant's Antibody Discovery Platform represents a dedicated platform for antibody discovery.
|
$10.90B |
$16.04
-0.50%
|
|
Antibody Discovery Platform aligns with Bio-Techne's growing antibody portfolio and discovery capabilities.
|
$8.72B |
$55.63
+6.51%
|
|
Sabre Bio adds an antibody discovery platform that Bio-Rad now offers, aligning with its portfolio.
|
$8.10B |
$284.88
|
|
Saber Bio antibody discovery platform represents a biotech discovery tool in Bio-Rad's portfolio.
|
$7.73B |
$284.07
-0.50%
|
|
Antibody Discovery Platform relevant to targeting moieties for AOC technology.
|
$5.18B |
$42.95
+3.74%
|
|
Provides proprietary antibody platforms (Biclonics®, Triclonics®, ADClonics®) for multispecific antibody discovery and engineering.
|
$4.71B |
$69.05
+1.40%
|
|
Company relies on a monoclonal antibody platform targeting latent growth factors, i.e., an Antibody Discovery Platform.
|
$3.75B |
$39.46
-3.94%
|
|
Antibody discovery platform supports development of multiple antibody-based therapies and pipelines.
|
$3.43B |
$31.62
+0.86%
|
|
LockBody is an antibody discovery platform licensed for research and development.
|
$2.98B |
$22.31
-2.75%
|
|
Uses proprietary antibody engineering/discovery platform to extend half-life and enable less frequent dosing of antibody therapeutics.
|
$2.37B |
$39.88
-0.18%
|
|
Antibody discovery platform aligns with their antibody discovery capabilities in Immune Medicine.
|
$2.03B |
$13.36
-3.68%
|
|
Antibody libraries for drug discovery reflect an antibody discovery platform offering.
|
$1.87B |
$31.19
-6.39%
|
|
Celldex markets an antibody discovery platform and proprietary antibody technology used to develop its therapies.
|
$1.74B |
$26.14
+1.79%
|
|
Immunocore's ImmTAX platform represents a technology/discovery platform for TCR-based immunotherapies, a distinct platform asset applicable across multiple oncology and immune-mediated programs.
|
$1.72B |
$34.27
-0.95%
|
|
Antibody Discovery Platform supporting ADC and degrader programs in oncology and immunology.
|
$1.61B |
$15.80
-9.97%
|
|
AbCellera's differentiated AI-powered platform is the core product enabling discovery of antibodies, including GPCRs/ion channels and T-cell engager platforms.
|
$1.45B |
$5.03
+2.86%
|
|
Platform-based approach (Antibody Discovery Platform) core to TRACTr/TRACIr drug modalities.
|
$1.45B |
$24.44
+3.25%
|
|
Antibody Discovery Platform represents a core platform for high-throughput antibody/TCR discovery.
|
$1.38B |
$7.28
|
|
Azymetric and related Drug Conjugate platforms function as core platform/discovery capabilities enabling multispecific antibodies and ADCs.
|
$1.26B |
$18.06
+4.39%
|
|
ModeX's platforms include an Antibody Discovery Platform (multi-specific antibodies), a direct product/technology offering.
|
$1.20B |
$1.51
-3.21%
|
|
Bispecific/TCR-discovery platform aligns with Antibody Discovery Platform.
|
$1.07B |
$10.36
-5.39%
|
|
The company highlights engineered monoclonal antibodies and antibody platforms to extend half-life, fitting the Antibody Discovery Platform category.
|
$987.38M |
$16.32
-0.28%
|
|
Antibody discovery platform enabling development of lead antibodies (Rosnilimab, ANB033, ANB101).
|
$921.67M |
$31.37
-2.15%
|
|
Antibody Discovery Platform encompasses antibody-related discovery and developability workflows.
|
$791.35M |
$13.52
-12.04%
|
|
Antibody Discovery Platform applies to Vir’s antibody engineering and development capabilities used across assets.
|
$758.93M |
$5.49
+5.98%
|
|
XmAb refers to an antibody discovery/engineering platform used to develop engineered antibodies and cytokine therapeutics.
|
$735.19M |
$10.33
-0.29%
|
|
Antibody Discovery Platform captures the underlying platform biology guiding antibody conjugates.
|
$626.30M |
$11.87
-11.42%
|
|
CMPX employs an in-house Antibody Discovery Platform to identify and optimize bispecific antibodies.
|
$586.32M |
$4.24
+4.18%
|
|
Core antibody discovery platform enabling multivalent antibody formats.
|
$516.07M |
$35.38
-0.76%
|
|
Sengenics antibody profiling integration supports an antibody discovery capability within LAB's SomaScan service ecosystem.
|
$497.57M |
$1.31
-5.07%
|
|
The company markets an Antibody Discovery Platform that enables de novo antibody design and high-throughput validation, aligning with its manufacturing/design capabilities.
|
$469.42M |
$3.68
-8.46%
|
|
SupraAntigen antibody discovery platform fits Antibody Discovery Platform.
|
$354.43M |
$3.55
+0.28%
|
|
Alector's ABC Platform is a proprietary platform for delivering diverse therapeutics across the blood-brain barrier, enabling brain-targeted delivery of antibodies and other cargo.
|
$301.98M |
$3.02
-5.48%
|
|
Antibody Discovery Platform reflects the company's platform-centric approach to antibody-based modalities.
|
$266.05M |
$3.30
+1.23%
|
|
Apexigen's APXiMAB antibody discovery platform is part of Pyxis's assets via acquisition and informs its antibody programs.
|
$229.21M |
$3.70
-3.39%
|
|
Antibody Discovery Platform: KINect platform underpins discovery of monoclonal antibodies (bosakitug, ATI-52.00) and bispecific candidates.
|
$207.90M |
$1.90
-1.04%
|
|
Core product: OmniAb's antibody discovery platform (Biological Intelligence) enabling generation of human antibodies via engineered transgenic animals and AI/ML.
|
$197.57M |
$1.61
-11.26%
|
|
INVYMAB is Invivyd's antibody discovery platform enabling rapid, serial monoclonal antibody development.
|
$195.54M |
$1.63
+9.40%
|
|
Antibody Discovery Platform captures CGEN's Unigen platform used to identify and optimize antibody targets and candidates.
|
$165.64M |
$1.85
-5.13%
|
|
SWAP and SWEETS are proprietary antibody-based platforms for tissue-selective Wnt activation, a core platform for Surrozen's therapeutics.
|
$117.88M |
$13.77
-1.10%
|
|
Company leverages protein-engineering capabilities for antibody development, implying an Antibody Discovery Platform function.
|
$109.21M |
$2.28
+1.33%
|
|
The company uses proprietary antibody discovery platforms (e.g., display technologies) to develop antibodies like BOT and BAL.
|
$108.84M |
$3.97
-6.81%
|
|
Antibody discovery platform (DART, TRIDENT) underpinning pipeline; direct platform offering.
|
$106.62M |
$1.69
-4.52%
|
|
Holds an Antibody Discovery Platform enabling the development of antibody-based therapies.
|
$86.33M |
$1.95
-1.52%
|
|
Antibody Discovery Platform is listed among Fortress's portfolio themes, indicating a focus on antibody discovery capabilities.
|
$80.13M |
$2.71
-3.56%
|
|
XBiotech markets a proprietary True Human antibody platform used to identify and clone natural human monoclonal antibodies (antibody discovery platform).
|
$77.44M |
$2.54
-3.05%
|
|
IGM's business rests on an engineered IgM antibody platform, a distinct discovery platform for novel antibody therapeutics.
|
$76.35M |
$1.27
|
|
Antibody discovery platform capability supporting antibody-based therapies and collaborations.
|
$71.14M |
$1.26
-9.35%
|
|
Antibody Discovery Platform; Sutro markets a platform for antibody discovery and site-specific conjugation (XpressCF+/ related capabilities).
|
$67.88M |
$0.80
-5.80%
|
|
LENSai functions as an antibody discovery platform, directly aligning with MindWalk's core product.
|
$59.46M |
N/A
|
|
Antibody Discovery Platform is cited as part of the platform used to discover antibody-based ADCs.
|
$50.76M |
$1.02
+11.90%
|
|
CAB represents an antibody discovery platform enabling conditional activation, aligning with Antibody Discovery Platform.
|
$50.68M |
$0.87
-17.38%
|
|
Company utilizes antibody-related platform technologies (e.g., nanobody-based approaches) as discovery platforms.
|
$46.41M |
$7.03
-5.64%
|
|
The core asset is an antibody-based platform (Gammabody) for engaging gamma-delta T cells, i.e., an Antibody Discovery Platform.
|
$40.76M |
$1.55
+0.65%
|
|
Company leverages an antibody discovery platform via its AbCellera collaboration, reflecting its focus on antibody-based therapeutic development.
|
$21.26M |
$0.51
-7.11%
|
|
DiversitAb is an antibody Discovery Platform used to generate fully human polyclonal antibodies; directly describes their core platform and product approach.
|
$19.14M |
$2.06
+4.04%
|
|
ProMIS relies on an Antibody Discovery Platform to identify disease-specific epitopes and generate targeted antibodies.
|
$16.28M |
$0.50
+4.64%
|
|
The company explicitly markets an Antibody Discovery Platform as a core capability in its AI-driven antibody development approach.
|
$14.19M |
$0.81
-0.30%
|
|
TMAb platform is Sensei's antibody discovery/engineering platform enabling conditionally active biologics.
|
$14.19M |
$11.26
-5.06%
|
|
Bolt's Boltbody ISAC platform is an antibody discovery/conjugate platform central to its products, qualifying as an 'Antibody Discovery Platform' investment theme.
|
$11.12M |
$5.80
-1.60%
|
|
Antibody discovery platform (EpiClick™) powering bispecific and monoclonal antibody development.
|
$7.93M |
$2.98
-7.45%
|
|
BriaCell's BriaPro and Bria-TILsRx platforms suggest involvement in an antibody discovery platform (B7-H3 antibodies).
|
$4.69M |
$12.40
-2.21%
|
|
ADAPTIR and ADAPTIR-FLEX are proprietary antibody/discovery platforms; this maps to Antibody Discovery Platform.
|
$636578 |
$1.57
-7.10%
|
Loading industry metrics...
Loading comparison data...
